Your browser doesn't support javascript.
loading
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon, C; Craig, V J; Méreau, H; Gräsel, J; Schacher Engstler, B; Hoffman, G; Nigsch, F; Gaulis, S; Barys, L; Ito, M; Aguadé-Gorgorió, J; Bornhauser, B; Bourquin, J-P; Proske, A; Stork-Fux, C; Murakami, M; Sellers, W R; Hofmann, F; Schwaller, J; Tiedt, R.
Afiliação
  • Dafflon C; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
  • Craig VJ; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
  • Méreau H; Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
  • Gräsel J; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
  • Schacher Engstler B; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
  • Hoffman G; Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Cambridge, MA, USA.
  • Nigsch F; Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Basel, Switzerland.
  • Gaulis S; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
  • Barys L; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
  • Ito M; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
  • Aguadé-Gorgorió J; Department of Oncology, University Children's Hospital Zurich, Zurich, Switzerland.
  • Bornhauser B; Department of Oncology, University Children's Hospital Zurich, Zurich, Switzerland.
  • Bourquin JP; Department of Oncology, University Children's Hospital Zurich, Zurich, Switzerland.
  • Proske A; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
  • Stork-Fux C; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
  • Murakami M; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
  • Sellers WR; Novartis Institutes for BioMedical Research, Disease Area Oncology, Cambridge, MA, USA.
  • Hofmann F; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
  • Schwaller J; Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
  • Tiedt R; Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland.
Leukemia ; 31(6): 1269-1277, 2017 06.
Article em En | MEDLINE | ID: mdl-27840424
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Rearranjo Gênico / Leucemia / Histona-Lisina N-Metiltransferase / Proteínas Proto-Oncogênicas / Resistencia a Medicamentos Antineoplásicos / RNA Interferente Pequeno / Inibidores Enzimáticos / Proteína de Leucina Linfoide-Mieloide / Metiltransferases Tipo de estudo: Prognostic_studies Idioma: En Revista: Leukemia Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Rearranjo Gênico / Leucemia / Histona-Lisina N-Metiltransferase / Proteínas Proto-Oncogênicas / Resistencia a Medicamentos Antineoplásicos / RNA Interferente Pequeno / Inibidores Enzimáticos / Proteína de Leucina Linfoide-Mieloide / Metiltransferases Tipo de estudo: Prognostic_studies Idioma: En Revista: Leukemia Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Suíça